New research clearly shows that non-diabetic people face high gastroparesis risks when they use GLP-1 agonists
Generic versions remain 5 to 7+ years away, but manufacturer competition and government pressure are driving prices lower faster than the patent timeline alone would suggest
Early intervention at the first signs of significant regaintypically defined as 5% or more weight increaseallows for timely adjustment of strategies and consideration of medication resumption if needed
doi: 10.1161/CIRCULATIONAHA.120.045888
They asserted that the the high clinical benefit rate from GLP-1RA therapy in our series raises a clarion call for rigorous, systematic investigation to define what the appropriate roles for such treatments in MCAS actually will be . Mast Cell Case Reports The case reports provided suggested these drugs can produce a wide range of benefits
This may include consuming a balanced diet rich in fruits, vegetables, whole grains, and lean proteins, and limiting the intake of sugary and processed foods